SOURCE: BioMedReports

BioMedReports

January 28, 2010 08:12 ET

Biomoda Is an Undervalued Cancer Diagnostics Company With Important Pending Developments (OTCBB: BMOD)

LOS ANGELES, CA--(Marketwire - January 28, 2010) - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting that New Mexico-based cancer diagnostics company Biomoda (OTCBB: BMOD), whose early cancer detection assay came from a spin-off of the Los Alamos National Labs, is on the verge of completing its Phase II studies for lung cancer patients.

The end of these studies will mark another important milestone for the company since upon completion they plan to submit Phase II data to European regulators in hopes of being granted a CE Mark. If successful, it would open the door for the company to begin commercializing the product throughout Europe by the middle of this year. The market potential for the assay is more than twice as large as it is in North America.

With an estimated 90 million smokers in the U.S., and 215 million in Europe, health officials say there is a serious need for advanced, early detection lung cancer diagnostics technology.

The company plans also to begin Phase III trials at multiple locations throughout the U.S. later this year. In time, it also plans to test and commercialize an entire portfolio of early cancer diagnostics tools, based on the same technology, for deadly breast, oral, prostate, bladder, colorectal, and cervical cancers.

All of these pending developments present opportunities for a significant capital appreciation in the stock price and expected positive Phase II results will certainly re-rate the stock.

A complete report about the company, complete with a video interview of its CEO, John Cousins, is available now at BioMedReports.Com:

http://biomedreports.com/articles/most-popular/26581-biomoda-undervalued-cancer-diagnostics-company-with-important-pending-developments-otcbbbmod.html

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/fda-calendar/fda-calendar.html

About BioMedReports.Com

BioMedReports.Com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report news and developments about publicly traded companies. See our complete disclosure statements at BioMedReports.

For more biomedical sector and investment news go to http://BioMedReports.com

Contact Information

  • Media Contact:
    Mary Davila
    Assistant Editor
    BioMedReports.Com
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556